Validation plan of bone marrow collection, processing and distribution using the failure mode and effect analysis methodology: a technical report

被引:3
作者
Teofili, Luciana [1 ,2 ]
Bianchi, Maria [1 ]
Valentini, Caterina Giovanna [1 ]
Bartolo, Martina [1 ]
Orlando, Nicoletta [1 ]
Sica, Simona [1 ,2 ]
机构
[1] Fdn Policlin Univ A Gemelli Ist Ricovero & Cura, Dipartimento Diagnost Immagini Radioterapia Oncol, Largo Gemelii 8, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dipartimento Sci Radiol & Ematol, Sez Ematol, Rome, Italy
关键词
validation plan; allogeneic hematopoietic stem cell transplant; bone marrow harvest; bone marrow processing; FMEA; BLOOD STEM-CELLS; CELLULAR THERAPY; TRANSPLANTATION; PRODUCTS; TOOL;
D O I
10.1016/j.jcyt.2021.10.005
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims: Bone marrow (BM) is commonly used in the pediatric and adult setting as a source of hematopoietic stem cells (HSCs). The standards of the Joint Accreditation Committee of the International Society for Cell & Gene Therapy & European Society for Blood and Marrow Transplantation (JACIE) include specific requirements regarding BM collection, processing and distribution. To run this process, each transplant team develops a series of JACIE-compliant procedures, customizing them with regard to local settings and paths. Moreover, JACIE standards require that transplant teams validate and periodically revise their procedures to keep the entire process under control. In this article, the authors describe the methodology adopted in our center to fulfill the aforementioned JACIE requirements. Methods: The authors developed a validation plan based on the failure mode and effect analysis (FMEA) methodology. According to the FMEA approach, the authors carefully revised activities and procedures connected to BM collection, processing and distribution at our institution. The entire process was initially divided into five main phases (assessment of donor eligibility, perioperative autologous blood donation, preparation of BM collection kit, BM harvesting and BM processing and distribution), comprising 17 subphases and 22 activities. Results: For each activity, one or more failure modes were identified, for a total of 28 failure modes, and a risk priority number (RPN) was then assigned to each failure mode. Although many procedures were validated, others were subjected to substantial changes according to the RPN rating. Moreover, specific indicators were identified for subsequent monitoring to contain the risk of failure of steps emerging as critical at FMEA. Conclusions: This is the first study describing use of the FMEA methodology within an HSC transplant program. Shaping the risk analysis based on local experience may be a trustworthy tool for identifying critical issues, directing strict monitoring of critical steps or even amending connected procedures. Overall, the FMEA approach enabled the authors to improve our process, checking its consistency over time. (c) 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:356 / 364
页数:9
相关论文
共 25 条
  • [1] Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
    Bashey, Asad
    Zhang, Mei-Jie
    McCurdy, Shannon R.
    St Martin, Andrew
    Argall, Trevor
    Anasetti, Claudio
    Ciurea, Stefan O.
    Fasan, Omotayo
    Gaballa, Sameh
    Hamadani, Mehdi
    Munshi, Pashna
    Al Malki, Monzr M.
    Nakamura, Ryotaro
    O'Donnell, Paul V.
    Perales, Miguel-Angel
    Raj, Kavita
    Romee, Rizwan
    Rowley, Scott
    Rocha, Vanderson
    Salit, Rachel B.
    Solh, Melhem
    Soiffer, Robert J.
    Fuchs, Ephraim Joseph
    Eapen, Mary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) : 3002 - +
  • [2] Carreras E, 2019, EBMT HDB HEMATOPOIET
  • [3] Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
    D'Souza, Anita
    Fretham, Caitrin
    Lee, Stephanie J.
    Arora, Mukta
    Brunner, Janet
    Chhabra, Saurabh
    Devine, Steven
    Eapen, Mary
    Hamadani, Mehdi
    Hari, Parameswaran
    Pasquini, Marcelo C.
    Perez, Waleska
    Phelan, Rachel A.
    Riches, Marcie L.
    Rizzo, J. Douglas
    Saber, Wael
    Shaw, Bronwen E.
    Spellman, Stephen R.
    Steinert, Patricia
    Weisdorf, Daniel J.
    Horowitz, Mary M.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (08) : E177 - E182
  • [4] Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance
    Golay, Josee
    Pedrini, Olga
    Capelli, Chiara
    Gotti, Elisa
    Borleri, Gianmaria
    Magri, Mara
    Vailati, Francesca
    Passera, Marco
    Farina, Claudio
    Rambaldi, Alessandro
    Introna, Martino
    [J]. CYTOTHERAPY, 2018, 20 (02) : 262 - 270
  • [5] Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from Wharton's Jelly
    Grau-Vorster, Marta
    Rodriguez, Luciano
    del Mazo-Barbara, Anna
    Mirabel, Clementine
    Blanco, Margarita
    Codinach, Margarita
    Gomez, Susana G.
    Querol, Sergi
    Garcia-Lopez, Joan
    Vives, Joaquim
    [J]. CELLS, 2019, 8 (05)
  • [6] Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation
    Holbro, Andreas
    Baldomero, Helen
    Lanza, Francesco
    Chabannon, Christian
    Snowden, John A.
    Buser, Andreas
    Infanti, Laura
    Worel, Nina
    Sureda, Anna
    Badoglio, Manuela
    Passweg, Jakob
    Bonini, Chiara
    [J]. CYTOTHERAPY, 2018, 20 (03) : 453 - 460
  • [7] Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC
    Kim-Wanner, Soo-Zin
    Bug, Gesine
    Steinmann, Juliane
    Ajib, Salem
    Sorg, Nadine
    Poppe, Carolin
    Bunos, Milica
    Wingenfeld, Eva
    Huemmer, Christiane
    Luxembourg, Beate
    Seifried, Erhard
    Bonig, Halvard
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15 : 174
  • [8] Failure mode and effect analysis in blood transfusion: a proactive tool to reduce risks
    Lu, Yao
    Teng, Fang
    Zhou, Jie
    Wen, Aiqing
    Bi, Yutian
    [J]. TRANSFUSION, 2013, 53 (12) : 3080 - 3087
  • [9] Fully automated, clinical-grade bone marrow processing: a single-centre experience
    Mazzanti, Benedetta
    Urbani, Serena
    Dal Pozzo, Simone
    Bufano, Paola
    Ballerini, Lara
    Gelli, Alessia
    Sodi, Irene
    Donnini, Irene
    Di Gioia, Massimo
    Guidi, Stefano
    Camisani, Julien
    Saccardi, Riccardo
    [J]. BLOOD TRANSFUSION, 2017, 15 (06) : 577 - 584
  • [10] Improving safety in blood transfusion using failure mode and effect analysis
    Mora, Asuncion
    Ayala, Luis
    Bielza, Rafael
    Ataulfo Gonzalez, F.
    Villegas, Ana
    [J]. TRANSFUSION, 2019, 59 (02) : 516 - 523